Tech Company Financing Transactions
Ambrosia Biosciences Funding Round
Blue Owl Capital, Deep Track Capital and Redmile Group joined a $100 million Series B funding round for Ambrosia Biosciences. This VC investment round was recorded on 3/31/2026.
Transaction Overview
Company Name
Announced On
3/31/2026
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for: Advancement of its novel oral small molecule GLP-1 into a Phase 1 clinical trial. Continued development of the its other small molecule programs, including GIP and amylin.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1941 Pearl St 300
Boulder, CO 80302
USA
Boulder, CO 80302
USA
Phone
Undisclosed
Website
Email Address
Overview
Ambrosia Biosciences Inc. is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kyle Lefkoff
Chief Medical Officer
Faraz Naqvi
Chief Scientific Officer
John Mayer
President
Nick Traggis
Browse more venture capital transactions:
Prev: 3/31/2026: Censys venture capital transaction
Next: 3/31/2026: OpenBox AI venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs